BioSpace News Archive

OncoSec Medical Inc. (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced today that Joon Kim, J.D., a partner at Lee & Ko, has been appointed to OncoSec’s Board of Directors.

Nuvo Pharmaceuticals Inc. announced that its wholly owned subsidiary, Nuvo Pharmaceuticals DAC has entered into a license and supply agreement with Heumann Pharma GmbH & Co. Generica KG for the exclusive right to distribute, market and sell Resultz® in Germany

In the hustle and bustle of holiday shopping and with 2019 fast approaching, For Eyes is here to make sure Americans don’t miss another important deadline.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it will receive $619,546, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA).

Health conditions that involve inflammation run the gamut, from multiple sclerosis and lupus to arthritis, diabetes, and cancer.

Focused on the Evolving Consumer Market, Company Prepares for Revolutionary Industry Changes

The latest version of the innovative radiation therapy treatment planning system (TPS) RayStation has been released*. RayStation 8B brings many ground-breaking advances, including some highly anticipated automation applications using machine learning and deep learning. Other major news in RayStation 8B include a new module for evaluation of robustness of treatment plans and photon Monte Carlo dose.

The Medical Science Liaison Society (MSL Society), the only 501(c)(3) non-profit organization exclusively dedicated to advancing the medical science liaison (MSL) profession, has released the first-ever official global non-regulatory industry-wide guidelines for MSL activities.

Green Growth Brands (CSE: GGB OTCQB:GGBXF) (GGB or the Company) recognizes the monumental shift in policy brought about by President Donald Trump’s signing of the 2018 Farm Bill yesterday.

Viriom, Inc. announced today that it plans to report results from its Phase 1b clinical trial of once weekly dosing of oral elsulfavirine (Elida®, VM1500), a potent long acting nonnucleoside reverse transcriptase inhibitor (NNRTI) in HIV-uninfected volunteers in March 2019.